BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Recent studies proposed that the rate of BCR-ABL1 decline is a critical prognostic predictor in CML treated with TKI and patients at risk of disease progression can be identified precisely by the lack of a half-log reduction of BCR-ABL1 transcripts at 3 months10,11.